The global GLP-1 market size is likely to grow from USD 49.3 billion in 2024 to USD 157.5 billion by 2035, growing at a CAGR of 11.1% during the forecast period, till 2035.
GLP-1 drugs market has garnered significant traction within the medical science domain. Concurrently, the rising demand and escalating prevalence of metabolic disorder including type 2 diabetes and obesity are fueling the need for treatments capable of effectively managing these conditions.
GLP-1drugs: market landscape. The current market landscape features the presence of more than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies, that are currently available in the market or under different stages of development. Majority (close to 60%) of the GLP-1 drug candidates are currently being evaluated in clinical stages of development; of these, most of the candidates target metabolic disorders, such as Type 2 diabetes and obesity. Notably, 11% GLP-1 drugs candidates are approved by various regulatory body across the globe.
Further, most (56%) of the GLP-1 drugs are currently being evaluated as a single agonist followed by dual-agonist (32%) and tri-agonist (12%) for the treatment of various metabolic and other disorders; examples of tri-agonist include (in alphabetical order, phase II / phase III studies) DR10624 (Doer Biologics), Efocipegtrutide, HM15211 (Hanmi Pharmaceutical), HM15275 (Hanmi Pharmaceutical), MWN101 (Shanghai Minwei Biotechnology), Retatrutide, LY3437943 (Eli Lilly) and UBT251 (United Bio-Technology). The GLP-1 market is highly fragmented, featuring the presence of well-established as well as emerging players. The GLP-1 market is currently dominated by the presence of mid-sized companies (27%). This is followed by small (25%) and very large companies (21%).
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
Key players
AstraZeneca
Biolingus
Boehringer Ingelheim
D&D Pharmatech
Eli Lilly
Gmax Biopharm
Hanmi Pharmaceutical
Innogen
Novo Nordisk
PegBio
Pfizer
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the GLP-1 Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
Click here to know more about this report -
https://www.rootsanalysis.com/reports/glp-1-market.html
GLP-1 drugs market has garnered significant traction within the medical science domain. Concurrently, the rising demand and escalating prevalence of metabolic disorder including type 2 diabetes and obesity are fueling the need for treatments capable of effectively managing these conditions.
GLP-1drugs: market landscape. The current market landscape features the presence of more than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies, that are currently available in the market or under different stages of development. Majority (close to 60%) of the GLP-1 drug candidates are currently being evaluated in clinical stages of development; of these, most of the candidates target metabolic disorders, such as Type 2 diabetes and obesity. Notably, 11% GLP-1 drugs candidates are approved by various regulatory body across the globe.
Further, most (56%) of the GLP-1 drugs are currently being evaluated as a single agonist followed by dual-agonist (32%) and tri-agonist (12%) for the treatment of various metabolic and other disorders; examples of tri-agonist include (in alphabetical order, phase II / phase III studies) DR10624 (Doer Biologics), Efocipegtrutide, HM15211 (Hanmi Pharmaceutical), HM15275 (Hanmi Pharmaceutical), MWN101 (Shanghai Minwei Biotechnology), Retatrutide, LY3437943 (Eli Lilly) and UBT251 (United Bio-Technology). The GLP-1 market is highly fragmented, featuring the presence of well-established as well as emerging players. The GLP-1 market is currently dominated by the presence of mid-sized companies (27%). This is followed by small (25%) and very large companies (21%).
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
Key players
AstraZeneca
Biolingus
Boehringer Ingelheim
D&D Pharmatech
Eli Lilly
Gmax Biopharm
Hanmi Pharmaceutical
Innogen
Novo Nordisk
PegBio
Pfizer
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the GLP-1 Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
Click here to know more about this report -
https://www.rootsanalysis.com/reports/glp-1-market.html